Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Genistein is a phytoestrogen of the isoflavone family which has been shown to have beneficial effects on endothelial function and bone metabolism. On the basis of the so far obtained results, aim of our research was to investigate for a two years period the effects of genistein on cardiovascular risk factors, endothelial function and oxidative stress markers, bone metabolism and finally clarify pathophysiology mechanisms (by dosage of cytokines and endothelial markers) by which this molecule could interfere on atherosclerosis and bone mass loss progression.
Particularly, and in extreme synthesis the following parameters have been studied during the treatment:
- inflammation markers as fibrinogen
- lipid profile - total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, lipoprotein(a)-
- endothelial function markers as VCAM-1 and ICAM-1
- oxidative stress by the evaluation of the F(2)-isoprostane
- cytokines as IL-6, OPG, RANK and RANKL
- bone mineral density, by DEXA, at lumbar spine and femoral neck
- Bone turnover markers as B-ALP, PYR, D-PYR
- PAP-test, transvaginal uterine ecography and mammography.
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- At least one year of menopause
- No use of hormone replacement therapy
- Bone mineral density T-score at the femoral neck minor than one S.D.
Exclusion Criteria:
- Concomitant disease
- Smoke habit
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Efficacy:
|
|
Safety:
|
|
bone mineral density
|
|
bone resorption/formation
|
|
cardiovascular risk factors
|
|
endometrial thickness
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Efficacy:
|
|
Safety:
|
|
hot flushes reduction
|
|
mammography
|
|
vaginal cells maturation value
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Francesco Squadrito, MD, University of Messina
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Study Completion
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Musculoskeletal Diseases
- Bone Diseases
- Bone Diseases, Metabolic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Estrogens, Non-Steroidal
- Estrogens
- Protein Kinase Inhibitors
- Anticarcinogenic Agents
- Phytoestrogens
- Genistein
Other Study ID Numbers
Other Study ID Numbers
- 2002067398
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.